Unexpectedly, our findings in hippocampal samples from patients with DS and AD suggest that STARD1 immunolabeling can act as a pathological mark of AD even better than Aβ42 deposition in post-morten samples (Figure 3), implying that the hippocampal alterations in the expression of STARD1 could occur in a temporal pattern parallel to the pathogenic amyloidogenic burden. Here, STAR is linked to Dravet syndrome.